MYGN Q1 2024 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q1 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$202M+11.6% YoY

Gross Profit

$138M68.1% margin

Operating Income

-$28M-13.8% margin

Net Income

-$26M-12.9% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$27M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$351M

Stockholders' Equity

$760M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$202M	$181M	+11.6%
Gross Profit	$138M	$122M	+12.8%
Operating Income	-$28M	-$52M	+46.6%
Net Income	-$26M	-$55M	+52.5%

Geographic Segments

UNITED STATES

$183M91%

Non-US

$19M9%